NCT05569512 2024-08-19
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
Dana-Farber Cancer Institute
Phase 1 Terminated
Clinical Trials
34 trialsNCT01041508 2024-02-01
Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT00697684 2023-11-28
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Beth Israel Deaconess Medical Center
Phase 1 Completed
NCT02083250 2022-01-06
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00498316 2020-02-28
Cord Blood Expansion on Mesenchymal Stem Cells
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01629082 2019-12-17
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00882076 2019-07-24
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
Milton S. Hershey Medical Center
Phase 1 Terminated
NCT01031368 2019-03-01
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
Nohla Therapeutics, Inc.
Phase 1 Completed
NCT00295841 2018-08-10
Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Wake Forest University Health Sciences
Phase 1 Completed
NCT00852709 2018-02-15
POE07-01
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT00908167 2018-01-12
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01169012 2017-08-22
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT01471067 2017-04-28
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01900509 2017-03-22
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00824135 2017-01-02
Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00577694 2015-10-12
Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT00991133 2015-04-30
A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)
Sanofi
Phase 1 Completed
NCT01065545 2015-04-10
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Northwestern University
Phase 1 Withdrawn
NCT00028418 2015-03-25
Clofarabine in Chronic Lymphocytic Leukemia
FDA Office of Orphan Products Development
Phase 1 Completed
NCT00338494 2015-01-29
Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma
Yale University
Phase 1 Completed
NCT01279096 2014-12-09
Vandevol
University Hospital, Lille
Phase 1 Completed
NCT00727766 2014-11-11
Oral Clofarabine for Acute Myeloid Leukemia
Washington University School of Medicine
Phase 1 Completed
NCT00477542 2014-09-18
A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT
Indiana University
Phase 1 Completed
NCT00477945 2014-09-11
Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL
Indiana University
Phase 1 Completed
NCT01132573 2014-07-17
Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00125827 2014-03-19
Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors
Sanofi
Phase 1 Completed
NCT01090167 2014-03-19
A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)
Sanofi
Phase 1 Completed
NCT01196013 2014-03-19
A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia
Sanofi
Phase 1 Completed
NCT00125840 2014-02-05
Clofarabine in Adult Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT00462787 2013-11-14
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00697671 2013-07-16
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00081887 2012-08-01
Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00081822 2012-04-20
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia
University of Alabama at Birmingham
Phase 1 Completed
NCT00293410 2010-05-06
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed